Literature DB >> 25231848

Expression and localization of cannabinoid receptor 1 in rats' brain treated with acute and repeated morphine.

Lingjing Jin1, Lizhen Pan, Yan Guo, Yuguo Zheng, Zhiyu Nie, Rongrong Zhu.   

Abstract

Morphine induces adaptive changes in gene expression throughout the reward circuitry of brain. Recent research has proven the functional interactions between opioid and endogenous cannabinoid system in the central nervous system (CNS). The cannabinoid receptor 1 (CB1-R) is one of the receptors that mediate the actions of cannabinoids and endocannabinoids in the CNS. Here, we investigated the expression of CB1-R in mRNA and protein levels in the brains of rats treated with acute and repeated morphine. Three groups of rats received intraperitoneal injections (ip injections) of saline, acute morphine (10 mg/kg) and repeated morphine (10 mg/kg, twice daily for 12 consecutive days), and the mRNA levels and protein expressions of CB1-R were examined. RT-PCR and western blot analyses supported that both mRNA and protein levels of CB1-R in cortex, cerebellum and hippocampus were increased by repeated morphine treatment. However, the mRNA level in cerebellum was down-regulated only after acute morphine treatment and would returned to basal levels later. We used immunohistochemistry techniques to determine the functional expression of CB1-R in morphine treated rat's brain. Enzyme-Linked Immunosorbent Assay (ELISA) revealed the significant increase of cytokine (IL-1beta, IL-6) levels in the repeated morphine treatment rats' cortex and hippocampus regions, which are both addiction-related brain areas. In addition, the results from RT-PCR and western blot assay indicated that the expression of CB1-R was directly increased by morphine treatment in vitro. All the results indicated that the CB1-R expression could be changed by morphine exposure and it might be involved in neural immune function, which provided a potential target for neurogenic disease treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25231848

Source DB:  PubMed          Journal:  Acta Neurobiol Exp (Wars)        ISSN: 0065-1400            Impact factor:   1.579


  6 in total

1.  Mutual assistance of nucleus accumbens cannabinoid receptor-1 and orexin receptor-2 in response to nicotine: a single-unit study.

Authors:  Reza Fartootzadeh; Hojjatallah Alaei; Parham Reisi
Journal:  Res Pharm Sci       Date:  2021-03-05

2.  The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area.

Authors:  Hong Zhang; Austin A Lipinski; Erika Liktor-Busa; Angela F Smith; Aubin Moutal; Rajesh Khanna; Paul R Langlais; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

3.  Increased Endocannabinoid Signaling Reduces Social Motivation in Intact Rats and Does Not Affect Animals Submitted to Early-Life Seizures.

Authors:  Fernanda Teixeira Ribeiro; Marcia Ivany Silva de Serro-Azul; Fernanda Beraldo Lorena; Bruna Pascarelli Pedrico do Nascimento; Alexandre José Tavolari Arnold; Geraldo Henrique Lemos Barbosa; Miriam Oliveira Ribeiro; Roberta Monterazzo Cysneiros
Journal:  Front Behav Neurosci       Date:  2020-12-09       Impact factor: 3.558

4.  Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB1 receptor density in cell membranes: an alternative to radioligand binding methods.

Authors:  Miquel Saumell-Esnaola; Ainhoa Elejaga-Jimeno; Leyre Echeazarra; Leire Borrega-Román; Sergio Barrondo; Maider López de Jesús; Imanol González-Burguera; Alberto Gómez-Caballero; María Aranzazu Goicolea; Joan Sallés; Gontzal García Del Caño
Journal:  Microb Cell Fact       Date:  2022-09-15       Impact factor: 6.352

Review 5.  Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.

Authors:  Ken Soderstrom; Eman Soliman; Rukiyah Van Dross
Journal:  Front Pharmacol       Date:  2017-10-10       Impact factor: 5.810

Review 6.  Biomarkers of the Endocannabinoid System in Substance Use Disorders.

Authors:  Francisco Navarrete; María S García-Gutiérrez; Ani Gasparyan; Daniela Navarro; Francisco López-Picón; Álvaro Morcuende; Teresa Femenía; Jorge Manzanares
Journal:  Biomolecules       Date:  2022-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.